

Glove-Induced Allergic Contact Hand Dermatitis: A Quality Improvement Initiative

Journal of Cutaneous Medicine and Surgery
00(0) 1–2
© The Author(s) 2020
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1203475420974650
journals.sagepub.com/home/cms



AnneLiese Smylie¹, Navjeet Gill², Rylee Oosterhuis²,
Pamela Mathura³, John Elliott⁴, Sebastian Straube⁵, and
Marlene Dytoc⁴

Keywords

allergic contact dermatitis, allergic contact hand dermatitis, occupational contact dermatitis, glove, quality improvement

We recently published on allergen-free glove selection for individuals suffering from allergic contact dermatitis (ACD) in the April 2020 issue of the *Journal of Cutaneous Medicine and Surgery*.¹ ACD accounts for approximately 20% of cases of occupational contact dermatitis with significant associated costs financially and on patients' quality of life.² Hands are the most frequently affected site with the rubber accelerants from protective gloves being one of the most common causes.^{3,4} The mainstay of ACD treatment is allergen avoidance, but this is complicated by the number of glove types and brands in use.⁵ Siegel et al noted that only 51% of patients were able to correctly identify the specific gloves responsible for their ACD.⁵ Currently, there is no structured approach for dermatologists to promote adherence and advocate for the use of appropriate gloves in patients with allergic contact hand dermatitis (ACHD) in the workplace. Our study aimed to have patients followed up after patch testing and offered a structured approach to promote adherence regarding the use of appropriate gloves, thereby promoting allergen avoidance and aiding in disease management.

The study was conducted from August 2017 to November 2018 at an outpatient dermatology clinic and consisted of 10 patients diagnosed via patch testing with glove-induced ACHD to rubber accelerants. Informed consent was obtained. The intervention consisted of 3 components: patch testing, a trial of accelerant-free gloves, and a letter of advocacy. At this initial follow-up after patch testing, patients were provided with a 1-month supply of accelerant-free gloves. Patients were assessed at the initial follow-up and subsequently 1 month later. Disease extent was measured with the Hand Eczema Severity Index (HECSI), and the impact of hand dermatitis on quality of life was measured with the Dermatology Life Quality Index (DLQI). Efficacy was assessed through repeat HECSI and DLQI scores at both the initial and final follow-up appointments. A letter of advocacy for the patient's employer was then created identifying the patient's particular allergen(s) related to

their glove-induced ACHD and the need for specific allergen-free gloves in the workplace.

At the initial visit, the average HECSI score was 54.7 (SD 46.2), and the average DLQI score was 13.2 (SD 6.6). Nine of 10 patients were seen at subsequent follow-up. At this follow-up, disease severity significantly improved. Among the 9 followed patients, there was improvement in disease severity, as seen in a decreased average HECSI score from 59.1 to 13.0 ($P < .01$). Patient dermatology quality of life also improved with a decrease in average DLQI from 13.4 to 8.8 ($P < .01$).

This initial study makes us hopeful that providing patients with a trial of allergen-free gloves and a letter of advocacy can improve the management of ACD. Our goal for this study was to provide the first step in the development of a sustainable management plan for glove-induced ACHD. We plan to continue this study by increasing the number of patients along with obtaining patient feedback to identify specific challenges.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

¹Department of Medicine, Division of Dermatology, University of Alberta, Edmonton, Canada

²Division of Dermatology, Faculty of Medicine, University of Alberta, Edmonton, Canada

³Department of Medicine, Alberta Health Services, University of Alberta, Edmonton, Canada

⁴Division of Dermatology, University of Alberta, Edmonton, Canada

⁵Division of Preventive Medicine, Department of Medicine, University of Alberta, Edmonton, Canada

Corresponding Author:

Marlene Dytoc, Division of Dermatology, University of Alberta, Edmonton AB T6G 2R3, Canada.

Email: research@mdskinhealth.com

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors received funding from the 2019 Edmonton Zone Quality Improvement funding competition, sponsored by the Chief Medical Officer of Quality Healthcare Improvement, Alberta Health Services.

ORCID iDs

Navjeet Gill  <https://orcid.org/0000-0001-9204-6484>

Rylee Oosterhuis  <https://orcid.org/0000-0002-7566-179X>

Marlene Dytoc  <https://orcid.org/0000-0002-2610-6212>

References

1. Lopushinsky KM, Gill N, Shea WK, Elliott JF, Straube S, Dytoc MT. Making glove decision less of a white knuckling experience: a systematic review and inventory of glove accelerator contents. *J Cutan Med Surg.* 2020;24(4):386-398. doi:10.1177/1203475420919398
2. Kersh AE, Helms S, de la Feld S. Glove-related allergic contact dermatitis. *Dermatitis.* 2018;29(1):13-21. doi:10.1097/DER.0000000000000335
3. Cashman MW, Reutemann PA, Ehrlich A. Contact dermatitis in the United States: epidemiology, economic impact, and workplace prevention. *Dermatol Clin.* 2012;30(1):87-98. doi:10.1016/j.det.2011.08.004
4. Cao LY, Taylor JS, Sood A, Murray D, Siegel PD. Allergic contact dermatitis to synthetic rubber gloves: changing trends in patch test reactions to accelerators. *Arch Dermatol.* 2010;146(9):1001-1007. doi:10.1001/archdermatol.2010.219
5. Siegel PD, Fowler JF, Storrs FJ, et al. Allergen content of patient problem and nonproblem gloves: relationship to allergen-specific patch-test findings. *Dermatitis.* 2010;21(2):77-83. doi:10.2310/6620.2010.09088